Completed PHASE4 INTERVENTIONAL 2-arm NCT04786938

Effect of Probiotics on the Fecal Resistome During Helicobacter Pylori Eradication Therapy

Effect of Saccaromyces Boulardii CNCM I-745 Supplementation on the Fecal Resistome of Patients Treated Against Helicobacter Pylori Infection

Sponsor: Biocodex

Conditions Gut Resistome

Interventions Saccharomyces Boulardii-Containing Product in Oral Dose Form

Updated 4 times since 2021 Last updated: Sep 27, 2021 Started: Apr 7, 2016 Primary completion: Jun 9, 2017 Completion: Jun 9, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Gut Resistome and is currently completed. Biocodex leads this study, which shows 4 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Nov 2021 — Jul 2024 [monthly]

Completed PHASE4
Apr 2021 — Nov 2021 [monthly]

Completed PHASE4

First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biocodex
Universidad San Francisco de Quito
Universidad Tecnológica Equinoccial

Data source: Universidad San Francisco de Quito

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.